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The transition to pulmonary respiration following birth requires
rapid alterations in the structure of the mammalian cardiovascular
system. One dramatic change that occurs is the closure and re-
modeling of the ductus arteriosus (DA), an arterial connection in
the fetus that directs blood flow away from the pulmonary
circulation. A role for prostaglandins in regulating the closure of
this vessel has been supported by pharmacological and genetic
studies. The production of prostaglandins is dependent on two
cyclooxygenases (COX-1 and COX-2), which are encoded by sepa-
rate genes. We report here that the absence of either or both COX
isoforms in mice does not result in premature closure of the DA in
utero. However, 35% of COX-2(2y2) mice die with a patent DA
within 48 h of birth. In contrast, the absence of only the COX-1
isoform does not affect closure of the DA. The mortality (35%) and
patent DA incidence due to absence of COX-2 is, however, signif-
icantly increased (79%) when one copy of the gene encoding
COX-1 is also inactivated. Furthermore, 100% of the mice deficient
in both isoforms die with a patent DA within 12 h of birth,
indicating that in COX-2-deficient mice, the contribution of COX-1
to DA closure is gene dosage-dependent. Together, these data
establish roles for COX-1, and especially for COX-2, in the transition
of the cardiopulmonary circulation at birth.
The ductus arteriosus (DA) is an arterial connection in thefetus between the pulmonary artery and the aorta. The DA
directs deoxygenated blood away from the pulmonary circu-
lation toward the descending aorta and to the umbilico-
placental circulation where oxygenation occurs. The DA plays
a critical role in the cardiovascular physiology of the fetus and
newborn (for review see ref. 1). In utero patency of the DA is
essential for proper fetal health, and premature DA closure
causes pulmonary hypertension, congestive heart failure, and
edema. In contrast, failure of the DA to close after birth,
designated patent DA, compromises postnatal health by con-
tributing to respiratory complications, including pulmonary
hypertension and edema (2).
A family of lipid mediators known as prostaglandins (PGs) are
among the factors that have been shown to influence the tone of
the DA. The initial reaction in the synthesis of all PGs is
catalyzed by prostaglandin GyH synthase, also known as cyclo-
oxygenase (COX), two isoforms of which have been identified.
Both COX-1 and COX-2 catalyze the synthesis of PGH2, a
product required for the formation of the various biologically
active PGs (3). Individual PGs act through specific receptors to
mediate their biological effects. The role for PGs in regulation
of DA tone was initially determined from the observation that
nonsteroidal anti-inflammatory drugs (NSAIDs), which act by
inhibiting COX (4), modulate DA tone in utero and following
birth (1).
The dilation of the DA in utero is an active process maintained
primarily by PGE2. The PG receptors that may have a role in
dilation of the DA include the PGE2 receptors, EP2 (5) and EP4
(6), and a receptor for prostacyclin (7). The tone of the DA may
also be regulated by PGs that bind to receptors in the DA and
initiate contraction of the smooth muscle of the vessel wall.
Contraction of the DA in vitro is induced by an agonist selective
for the PGE2 receptors, EP1 and EP3, and by a stable analogue
of PGH2 (8). Although mice deficient in each of the four EP
receptors and in the prostacyclin receptor have been generated
(9), only EP4 receptor-deficient mice show a DA phenotype,
with greater than 95% of these mice dying with a patent DA
within 48 h of birth (10, 11).
The disruption of the genes encoding COX-1 (Ptgs1) (12) and
COX-2 (Ptgs2) (13, 14) has also been accomplished, and these
mice have provided genetic models to study the functions of each
COX isoform. Although no prenatal or postnatal phenotype
involving the DA was originally reported in either COX-
deficient line, functional compensation of one isoform for the
other may have obscured a neonatal DA phenotype. To better
understand the contribution of the COX isoforms and the PGs
they produce to the function of the ductus, we have generated
mice with reduced expression of COX-1 andyor COX-2, as well
as mice deficient in both COX isoforms. Herein, we show that
the deficiency of COX-2 alone is sufficient to alter normal
closure of the DA after birth, and the role for COX-1 becomes
evident only in the absence of COX-2. Therefore, although both
COX isoforms contribute to the function of the ductus, COX-2
is the more essential isoform for initiation of DA closure.
Methods
Breedings. Mice deficient in COX-1 and COX-2 were maintained
on a mixed genetic background of C57BLy6J and 129yOla (12, 13).
Wild-type mice were generated from COX heterozygotes to ensure
a similar genetic background. Because COX-2(2y2) females
are infertile (15), mice lacking both COX isoforms were gener-
ated from females that expressed one allele of Ptgs2. The
COX-1(1y2)yCOX-2(1y2) and COX-1(2y2)yCOX-2(1y2)
females were fertile and produced litters of normal size, but
parturition was delayed in both genotypes. Litters were there-
fore delivered by Cesarean section to prevent pup loss. The
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detection of the copulation plug the morning after pairing was
designated as gestation day 0.5. The genotypes of the male mice
used for breeding included COX-1(2y2)yCOX-2(1y2), COX-
1(1y2)yCOX-2(2y2), COX-1(1y1)yCOX-2(2y2), and COX-
1(1y2)yCOX-2(1y2).
Pathological Analysis. Histological analyses were performed on
formalin-fixed, paraffin-embedded tissues. Decapitated torsos
were transected just below the rib cage before formalin fixation.
For total pathological analysis, the head, upper torso, and lower
torso were processed, paraffin-embedded, and serial sectioned.
DA analysis was performed on transverse sections of the thorax.
The entire length of the DA from the descending aorta to the
pulmonary trunk was serial sectioned. The figures shown (he-
matoxylin and eosin-stained) are representative of the sections
most central to the DA lumen.
Indomethacin-Induced Fetal DA Contraction and Postnatal Mortality.
Indomethacin-induced fetal DA contraction was determined on
gestation day 18.5. Fetuses were delivered by Cesarean section
4 h after maternal indomethacin (20 mgykg oral gavage, 5% gum
arabic) administration and sacrificed immediately for histolog-
ical analysis.
Indomethacin-induced postnatal mortality was determined
after a normal gestation length of 19.5 days. Maternal indo-
methacin (20 mgykg oral gavage, 5% gum Arabic) was admin-
istered 4 h before Cesarean delivery on day 19.5. The litters were
from COX-1(1y2)yCOX-2(1y2) and COX-1(2y2)yCOX-
2(1y2) females mated to COX-1(2y2)yCOX-2(1y2), COX-
1(1y2)yCOX-2(2y2), or COX-1(1y2)yCOX-2(1y2) males.
Immunohistochemical Analysis of COX-1 and COX-2. Immunohisto-
logical analyses of DA tissue for detection of COX-1 and COX-2
were performed on 10% neutral buffered formalin-fixed, par-
affin-embedded 10-mm-thick sections. Antigen retrieval was
carried out in citrate buffer by heating to 96°C in a microwave
oven, followed by cooling for 20 min at room temperature.
Sections were first treated with 1% BSA, 1% nonfat dried milk,
and 1% normal goat serum. Primary antibody against COX-1
(Cayman Chemical, Ann Arbor, MI) (1:2,000) or COX-2 (Cay-
man Chemical) (1:2,000) was then applied and incubated over-
night at room temperature and then processed as recommended
in the Vectastain ABC Elite kit (Vector Laboratories) for
detection with 3,3-diaminobenzidine (Sigma). Slides were coun-
terstained with Mayer’s hematoxylin (Sigma). Tissue sections
from COX-1(2y2) or COX-2(2y2) mice provided negative
controls for the specificity of the respective antibodies.
Genotype Analysis of Ptgs1 and Ptgs2. Tissue from pups was
collected at the time of sacrifice for genotyping of Ptgs1 and Ptgs2
by PCR (16). Tissue from adult mice was collected by tail biopsy.
The PCR primers used to identify genotypes were as follows:
Ptgs1 targeted forward, 59-GCAGCCTCTGTTCCACATA-
CAC-39; Ptgs1 wild-type forward, 59-AGGAGATGGCTGCT-
GAGTTGG-39; Ptgs1 reverse, 59-AATCTGACTTTCTGAGT-
TGCC-39; Ptgs2 targeted forward, 59-ACGCGTCACCTT-
AATATGCG-39; Ptgs2 wild-type forward, 59-ACACCTTCAA-
CATTGAAGACC-39; Ptgs2 reverse, 59-ATCCCTTCACTA-
AATGCCCTC-39.
Neonatal Mortality Analysis. Pups from COX-1(1y2)yCOX-
2(1y2) and COX-1(2y2)yCOX-2(1y2) females that were
delivered by Cesarean section after a normal gestation length of
19.5 days were maintained on pure oxygen for 1 h and then
fostered with a CD-1 female. Pups were monitored for mortality
during the first 48 h after delivery. Neonatal mortality for each
genotype is the percentage of the number of pups that died
during the first 48 h following birth compared with the number
at birth.
Patent DA Incidence. Pups obtained after natural death or follow-
ing sacrifice at 5 h after birth were used for analysis of the DA.
Data are expressed as the percentage of the number of pups with
a patent DA compared with the total number of pups at birth.
Results
Analysis of COX-1-Deficient Mice and COX-2-Deficient Mice. We have
previously reported that absence of expression of COX-1 does not
affect the survival or growth of COX-1-deficient mice (12) and that
necropsy and histological analysis of these mice revealed no pa-
thologies. In the current studies, we extend these findings to include
the observation that the DA of COX-1-deficient mice closed and
remodeled after natural birth and was indistinguishable from that
of wild-type mice (Fig. 1A). The number of live COX-2-deficient
pups at 12 h after natural birth was in agreement with Mendelian
expectations but, in contrast to COX-1-deficient mice, continued
observation of these litters revealed a high mortality (35%) in the
COX-2(2y2) pups over the next 24 to 48 h.
Histological examination of the pups lacking COX-2 that died
in the first 48 h after natural birth indicated a patent DA.
Examination of the liver, particularly in pups that died on the
second day after birth, revealed macrovesicular and microve-
sicular lipid deposits, consistent with acute ischemia, secondary
to heart failure. COX-2-deficient pups that survived the peri-
natal period also survived to weaning. Examination of the DA
in the surviving COX-2-deficient mice showed a normal trans-
formation of the DA into the ligamentum arteriosum.
Development of Mice with Reduced Expression of Both Ptgs1 and
Ptgs2. Whereas significant mortality was observed in the COX-2-
deficient population, 65% of COX-2-deficient mice survived to
adulthood. This suggested that COX-1 may partially compensate
for the COX-2 deficiency to allow DA closure and survival of the
pups. To investigate this possibility and to better understand the
role of each COX isoform in fetal and neonatal DA function, we
generated mice lacking both isoforms and mice with reduced
expression of one or both isoforms. The neonates with reduced
COX expression were obtained by mating COX-1(1y2)yCOX-
2(1y2) or COX-1(2y2)yCOX-2(1y2) females to COX-
1(2y2)yCOX-2(1y2) males to produce pups of the various
Ptgs genotypes. Previously, it has been shown that mice lacking
COX-1 have delayed parturition, which results in reduced perinatal
survival (17). To circumvent this problem, in the present study, pups
were delivered by Cesarean section after the normal gestation
length of 19.5 days. We first examined the impact of the deficiency
of COX-1 and COX-2 expression on fetal development. As shown
in Table 1, these matings produced live pups of all expected Ptgs
genotypes, including those lacking both Ptgs1 and Ptgs2, in accor-
dance with the Mendelian ratios. Therefore, prostanoids produced
by either fetal COX-1 or COX-2 are not required for embryo
implantation or for survival of the fetus.
Sensitivity of the DA to NSAIDs in Mice with Reduced Expression of
Both Ptgs1 and Ptgs2. Pharmacological studies have shown that
late gestation human and mouse fetuses are highly susceptible to
premature contraction of the DA following acute maternal
administration of NSAIDs, such as indomethacin (10, 18).
Therefore, the survival to birth of the pups lacking both COX
isoforms is surprising, as it suggests that prostanoids produced by
the fetal COX-1 and COX-2 pathways are not required for
patency of the DA in utero. Furthermore, on gestation day 18.5,
the DA of the COX-deficient fetuses could not be distinguished
from those of wild-type fetuses by histological examination (data
not shown). To determine if premature closure of the DA on
exposure to indomethacin is due to the inhibition of fetal COX-1




















andyor COX-2, we administered indomethacin to the pregnant
females and examined the DA in fetuses with varying expression
of the two genes. In agreement with previous reports, indometh-
acin induced DA closure in day 18.5 wild-type fetuses (Fig. 2A).
In the present study, we found DA closure in all fetuses wild-type
or heterozygous (Fig. 2 B and C) for Ptgs2, irrespective of their
Ptgs1 genotype (Table 2). However, indomethacin did not induce
DA closure in fetuses that lacked COX-2 expression (Fig. 2
D–F). Therefore, indomethacin-induced closure of the DA
requires fetal expression of COX-2, and neither maternal nor
fetal expression of COX-1 is required for the DA to be sensitive
to indomethacin.
Because fetuses expressing COX-2 were sensitive to indo-
methacin-induced premature DA closure, we determined the
susceptibility of different Ptgs genotypes to indomethacin-
induced postnatal mortality. In utero closure of the fetal DA is
known to produce pulmonary hypertension, which impairs post-
natal respiration (19). The maternal administration of indometh-
acin 4 h before Cesarean delivery on day 19.5 was lethal for all
of the neonates that expressed COX-2 (Table 2). These pups
died within minutes after delivery and their DAs were con-
tracted, suggesting that premature DA closure in the fetus
caused the death of the neonate. In contrast, 100% of pups that
were deficient in COX-2 survived until sacrifice at 5 h after birth
(Table 2). Therefore, after acute maternal indomethacin admin-
istration, the absence of COX-2 prevents premature DA closure
and neonatal lethality, supporting the requirement for COX-2 in
indomethacin-induced DA closure.
Postnatal Mortality of Mice with Reduced Expression of Both Ptgs1
and Ptgs2. The health of neonates lacking COX was monitored
following Cesarean delivery. The newborn pups of all genotypes,
including pups lacking both COX isoforms, were normal in size
and had no gross deformities at birth. Consistent with our
observations of naturally delivered litters, the absence of COX-1
did not reduce survival of the pups. In contrast, but consistent
with the mortality observed in naturally delivered litters, loss of
COX-2 also significantly decreased postnatal survival following
Fig. 1. COX-dependent DA closure in neonatal mice. The DA was analyzed in pups 5 h after birth. (A) COX-1(1y1)yCOX-2(1y1). (B) COX-1(2y2)yCOX-2(2y2).
(C) COX-1(1y2)yCOX-2(2y2). (D) COX-1(1y2)yCOX-2(2y2). (E) COX-1(1y2)yCOX-2(2y2). (F) COX-1(2y2)yCOX-2(1y2). Ao, aorta. (Scale bar, 100 mm.)
Genotype figure labels, Ptgs1 genotypeyPtgs2 genotype.
Table 1. Progeny genotypes agree with Mendelian expectations
Maternal genotype: COX-1(1y2)yCOX-2(1y2) COX-1(2y2)yCOX-2(1y2)
Paternal genotype: COX-1(2y2)yCOX-2(1y2) COX-1(2y2)yCOX-2(1y2)
Offspring genotype Expected ratio Obtained ratio* Expected ratio Obtained ratio†
COX-1(1y2)yCOX-2(1y1) 0.125 0.110 NA NA
COX-1(1y2)yCOX-2(1y2) 0.250 0.253 NA NA
COX-1(1y2)yCOX-2(2y2) 0.125 0.115 NA NA
COX-1(2y2)yCOX-2(1y1) 0.125 0.133 0.250 0.241
COX-1(2y2)yCOX-2(1y2) 0.250 0.293 0.500 0.474
COX-1(2y2)yCOX-2(2y2) 0.125 0.110 0.250 0.285
Litters were delivered after a normal gestation length of 19.5 days. Expected ratios are the Mendelian
expectations. All obtained ratios are not significantly different from expected ratios (x2 statistic, P , 0.01).
*269 mice analyzed.
†341 mice analyzed. NA, not applicable.

































Cesarean delivery. Thirty-five percent of the COX-2(2y2) pups
delivered by Cesarean section died within 48 h (Table 3).
Survival of COX-2(2y2) mice was further compromised by
decreased COX-1 expression. Seventy-nine percent of the pups
lacking COX-2 and having only one functional copy of the Ptgs1
gene died within 48 h of birth. Furthermore, 100% of the pups
deficient in both COX-1 and COX-2 died during the postnatal
period. More than 50% of these double homozygous mutant
pups became cyanotic and died within 30 min of Cesarean
delivery. The breathing of these pups appeared labored before
cyanosis and death. Treatment of the pups with pure oxygen for
the first hour improved their survival, with the majority of these
pups surviving over 5 h. However, 100% of these pups died by
12 h after birth (Table 3).
Analysis of Neonates with Reduced Expression of Both Ptgs1 and
Ptgs2. To determine the cause(s) of death of the COX-deficient
pups, pathological analysis was performed on pups sacrificed 5 h
after birth. A complete histological evaluation of the various organ
systems was carried out with particular attention given to the
COX-1(2y2)yCOX-2(2y2) animals. Similar to findings in pups
lacking the individual isoforms, no pathologies were apparent in the
brain, urinary bladder, kidney, spleen, pancreas, intestines, or
stomach in the COX-1(2y2)yCOX-2(2y2) pups. Despite the
observation of respiratory distress in COX-1(2y2)yCOX-2(2y2)
pups, their heart and lungs appeared histologically normal. The only
cardiovascular pathology observed was a patent DA, and the lumen
of the vessel was similar in diameter to that of the adjacent aorta
(Fig. 1B).
As expected, the DA was found to be contracted in all of the
wild-type pups at 5 h after birth (Table 3, Fig. 1 A). The DA of
pups lacking COX-1, even those with one disrupted copy of the
Ptgs2 gene (Fig. 1F), could not be distinguished from the DA of
the wild-type animals (Fig. 1 A). The patency of the DA in mice
lacking COX-2 varied between individual animals. In agreement
with the survival studies, the DA was patent in 33% of the
COX-2(2y2) pups analyzed at 5 h after birth. Furthermore, the
incidence of patent DA was increased in the COX-2(2y2) mice
heterozygous for the Ptgs1 mutant allele. A 74% incidence of
patent DA was observed in COX-1(1y2)yCOX-2(2y2) mice
5 h after birth (Table 3). Within this group of mice, there was
considerable variability in the extent to which the DA had closed.
In about one-half (6 of 14) of these mice, no contraction of the
vessel was apparent, and the lumen of the vessel was similar in
size to the adjacent aorta (Fig. 1C). In the remaining COX-
1(1y2)yCOX-2(2y2) mice, the ductus remained patent, but
Fig. 2. COX-2-dependent DA closure after maternal indomethacin treatment. Histological sections are from fetal DA on gestation day 18.5. (A) COX-1(1y1)y
COX-2(1y1). (B)COX-1(1y2)yCOX-2(1y2). (C)COX-1(2y2)yCOX-2(1y2). (D)COX-1(1y1)yCOX-2(2y2). (E)COX-1(1y2)yCOX-2(2y2). (F)COX-1(2y2)yCOX-2(2y2).
Ao, aorta. (Scale bar, 100 mm.) Genotype figure labels, Ptgs1 genotypeyPtgs2 genotype.
Table 2. Resistance to indomethacin-induced fetal DA closure






COX-1(1y1)yCOX-2(1y1) 100 (6y6) 0 (0y7)
COX-1(1y2)yCOX-2(1y1) 100 (5y5) 0 (0y5)
COX-1(2y2)yCOX-2(1y1) 100 (6y6) 0 (0y8)
COX-1(1y1)yCOX-2(1y2) 100 (6y6) 0 (0y6)
COX-1(1y2)yCOX-2(1y2) 100 (6y6) 0 (0y8)
COX-1(2y2)yCOX-2(1y2) 100 (8y8) 0 (0y14)
COX-1(1y1)yCOX-2(2y2) 0 (0y6) 100 (5y5)
COX-1(1y2)yCOX-2(2y2) 0 (0y6) 100 (7y7)
COX-1(2y2)yCOX-2(2y2) 0 (0y6) 100 (12y12)
*Indomethacin-induced fetal DA closure was determined on gestation day
18.5 after maternal indomethacin administration 4 h prior to Cesarean
delivery. In parentheses are number closedynumber analyzed.
†Neonatal survival after maternal indomethacin administration was deter-
mined after Cesarean delivery on gestation day 19.5. The surviving pups were
sacrificed 5 h after birth. In parentheses are number aliveynumber born.
Table 3. COX-2 deficiency increases neonatal mortality and
patent DA incidence with Ptgs1 gene dosage-dependent
compensation
Offspring genotype % mortality*
Patent DA,†
% incidence
COX-1(1y1)yCOX-2(1y1) 3 (1y31) 0 (0y8)
COX-1(1y2)yCOX-2(1y1) 6 (3y47) 0 (0y6)
COX-1(2y2)yCOX-2(1y1) 3 (1y40) 0 (0y10)
COX-1(1y1)yCOX-2(1y2) 4 (2y49) 0 (0y6)
COX-1(1y2)yCOX-2(1y2) 1 (1y99) 0 (0y8)
COX-1(2y2)yCOX-2(1y2) 3 (3y88) 0 (0y21)
COX-1(1y1)yCOX-2(2y2) 35‡ (20y57) 33 (5y15)
COX-1(1y2)yCOX-2(2y2) 79‡ (26y33) 74 (14y19)
COX-1(2y2)yCOX-2(2y2) 100‡ (38y38) 100 (23y23)
Neonatal mortality for each genotype is the percentage of mice that died
during the 48 h following birth compared to the number at birth. Neonatal
patent DA incidence was determined 5 h after Cesarean delivery or natural
birth on gestation day 19.5.
*In parentheses are number deadynumber born.
†In parentheses are number patentynumber analyzed.
‡Significantly different (x2 statistic, P , 0.01).




















partial contraction of the vessel resulting in a thickening of the
vessel wall was apparent (Fig. 1D). The expression of a single
copy of Ptgs1 did allow the DA to close (Fig. 1E) in 26% of the
COX-1(1y2)yCOX-2(2y2) mice (Table 3). Therefore, halving
the gene dosage of Ptgs1 in the COX-2(2y2) mice increased the
incidence of patent DA from 33% to 74%, in agreement with
their increased mortality (79%) (Table 3).
Immunohistochemistry of COX-1 and COX-2 in the DA. The expression
of COX-1 and COX-2 in the DA was examined by immunohis-
tochemistry to determine the contribution of localized COX
expression to the physiology of DA closure. At 2.5 h after birth,
COX-2 expression was evident in the smooth muscle cells of
wild-type mice (Fig. 3A). Examination at higher magnification
showed a concentration of staining in the perinuclear region of
the smooth muscle cells (Fig. 3A, Inset). COX-2 was not detected
in endothelial cells lining the DA lumen nor in fibroblasts of the
tunica adventitia. As expected, COX-2 expression was not
detected in the DA of COX-2-deficient mice (Fig. 3B). Analysis
of wild-type mice with an antibody specific for COX-1 failed to
detect expression of this isoform in the DA (Fig. 3C); although
the antibody did detect COX-1 expression in the epidermis in
similarly treated tissue sections (Fig. 3C, Inset). Our demonstra-
tion of a role for COX-1 in closure of the DA and our failure to
detect COX-1 expression in the ductus suggest that COX-1-
dependent prostanoids produced by other tissue(s) may contrib-
ute to closure of the ductus after birth.
Discussion
In the present study, we investigated the role of prostanoids in
fetal development and survival in the perinatal period by
generating mice with various homozygous and heterozygous
mutations in the genes encoding COX-1 and COX-2. When
examined just before the time of normal delivery, no develop-
mental abnormalities were detected in pups deficient in both
COX isoforms, indicating that if prostanoids are essential for in
utero development, they are supplied maternally. However,
survival in the postnatal period was dramatically reduced in mice
with decreased COX expression.
We first examined survival of mice deficient in either the
COX-1 isoform or the COX-2 isoform. Previously, it has been
reported that mice lacking COX-2 showed increased neonatal
mortality, the cause of which was not established (14). The
present data show that COX-2 deficiency alone caused a patent
DA and death in approximately 35% of the pups, which likely
accounts for the previously reported neonatal death. Further-
more, necropsy of these pups revealed secondary pathologies
consistent with a left to right shunt of blood through the DA. In
contrast to mice deficient in COX-2, the DA closed normally in
100% of mice deficient in COX-1 alone.
To elucidate the combined contribution of the two COX
isoforms to DA closure and neonatal survival, we also deter-
mined the status of the DA and the survival of pups with reduced
expression of both COX isoforms. Although closure of the DA
and survival of COX-2-deficient mice were compromised, the
majority (65%) of these mice survived to adulthood. This
suggests that in surviving mice deficient in COX-2, the PGs
required for closure of the DA may be provided by COX-1. In
support of this hypothesis, we found that reducing the functional
gene copy number of Ptgs1 significantly increased both mortality
and the incidence of patent DA in COX-2-deficient mice (Table
3). Therefore, in COX-2-deficient mice, the expression of
COX-1 provides partial compensation to close the DA and
increase postnatal survival.
Previously, it has been shown that mice deficient in the PGE2
receptor, EP4, also have an increased incidence of patent DA
(10, 11). The deficiency of the EP4 receptor leads to the death
of greater than 95% of the pups within 48 h of birth (10). In pups
lacking either COX-2 or the EP4 receptor, survival in the early
perinatal period is normal, but death is observed primarily
between 24 and 48 h after birth. Secondary lesions in both the
EP4 receptor-deficient and the COX-2-deficient pups are con-
sistent with a left to right shunt leading to pulmonary congestion,
decreased systemic blood flow, and death due to congestive heart
failure. In contrast, the majority of pups lacking both COX
isoforms died within minutes of birth, although survival was
extended by treatment with oxygen. Thus, although both the EP4
receptor-deficient and COX-1yCOX-2-deficient pups die in
the postnatal period, differences in survival suggest that the
mechanisms are not identical. We therefore propose that
while COX-2, and to some extent perhaps COX-1, produces
PGE2 essential for EP4 activation and remodeling of the DA
after birth, additional prostanoids may play a role in closure of
the DA.
Our observation of a patent DA in COX-1yCOX-2-deficient
mice suggests that COX-dependent metabolite(s) may initiate
DA contraction immediately following birth. In addition, the
expression of COX-2 in smooth muscle cells of the DA suggests
that synthesis of contractile PG(s) may occur in the DA itself.
Previous studies have shown that DA smooth muscle contracts
in response to stable analogues of endogenous COX-dependent
metabolites. DA tissue in vitro contracts in response to treatment
with an EP1yEP3-selective PGE2 analogue (sulprostone) or a
Fig. 3. Immunohistochemical analysis of COX-1 and COX-2. DA sections
obtained from neonates sacrificed 2.5 h after birth. (A) COX-1(1y1)yCOX-
2(1y1), anti-COX-2; (Inset) perinuclear staining. (B) COX-1(1y1)yCOX-2(2y
2), anti-COX-2. (C) COX-1(1y1)yCOX-2(1y1), anti-COX-1; (Inset) epidermis of
COX-1(1y1)yCOX-2(1y1), anti-COX-1. (Scale bar, 100 mm.) Genotype figure
labels, Ptgs1 genotypeyPtgs2 genotype.

































stable analogue of PGH2 (U46619) (8). However, because the
predominant effect of PGE2 on the DA is to induce dilation, the
importance of EP1 or EP3 receptors in DA contraction in vivo
is uncertain. Therefore, we propose that COX-2 expressed in the
DA smooth muscle produces a metabolite, possibly PGH2, that
contributes to DA contraction.
Numerous observations in humans and rodents indicate that
maternal administration of NSAIDs contract the DA in late-
term fetuses (18, 20–22). Therefore, the finding of patent DA in
the COX-deficient fetuses was surprising because the lack of PG
production in COX-deficient fetuses was expected to cause
premature DA contraction similar to the effects of NSAIDs.
PGE2 in the fetal circulation maintains dilation of the DA in
utero, and the placenta, in part, supplies the fetus with this
dilatory PGE2 (1). Our findings suggest that COX-2 in the DA
produces constrictor PG(s) important for DA contraction. Thus,
the contraction of the DA following maternal indomethacin
administration may result from the inhibition of dilatory PGE2
synthesis in the placenta without sufficient inhibition of ductal
COX-2 to attenuate DA contraction.
Although NSAIDs are effective treatment for premature
labor, their clinical use is limited, in part, by the adverse effect
of inducing fetal DA contraction. COX-2-selective inhibitors
have been suggested to provide a therapeutic advance for the
treatment of premature labor with fewer fetal adverse effects
than nonselective COX inhibitors (23–25). NSAIDs cross the
placenta to enter the fetal circulation in concentrations similar
to the maternal circulation (26, 27). The experiments reported
here show that COX-2 expression in the DA is important for DA
closure in mice. The maternal use of COX-2-selective inhibitors
that enter the fetal circulation may inhibit COX-2 activity in the
DA. If the contributions of COX-2 to the physiology of the DA
are conserved across species, maternal use of COX-2-selective
inhibitors near the time of delivery has the potential to increase
the incidence of patent DA after birth. Therefore, our findings
suggest that further investigation is required before COX-2-
selective inhibitors should be considered safe for human use
during pregnancy.
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